Small molecule · Inhibitor of iron-dependent KDM enzymes (lysine demethylases) · developed by Telomir Pharmaceuticals
Zn-Telomir is an oral small molecule that inhibits iron-dependent KDM enzymes, reducing tumor DNA methylation and killing cancer cells in an iron-dependent manner. It is studied in triple-negative breast cancer, including advanced and metastatic disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07581314 | Phase 1/2 | Triple-Negative Breast Cancer (TNBC) | Not yet recruiting | TELO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Triple-Negative Breast CancerMetastatic Triple-negative Breast CancerTriple-Negative Breast Cancer (TNBC)
Updated Nov 1, 2026. Something wrong or missing? Report it on the TELO page.
See TELO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TELO catalysts and pipeline →